Daily Stock Analysis, HRTX, Heron Therapeutics Inc, priceseries

Heron Therapeutics Inc. Daily Stock Analysis
Stock Information
Open
22.99
Close
23.38
High
23.66
Low
22.83
Previous Close
23.20
Daily Price Gain
0.18
YTD High
28.70
YTD High Date
Feb 22, 2019
YTD Low
15.68
YTD Low Date
Aug 7, 2019
YTD Price Change
-2.62
YTD Gain
-10.08%
52 Week High
29.49
52 Week High Date
Dec 4, 2018
52 Week Low
15.68
52 Week Low Date
Aug 7, 2019
52 Week Price Change
-1.30
52 Week Gain
-5.27%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jul 13. 2017
14.90
Jul 27. 2017
16.50
10 Trading Days
10.71%
Link
LONG
Sep 25. 2017
15.45
Oct 9. 2017
16.45
10 Trading Days
6.49%
Link
LONG
Dec 18. 2017
17.00
Jan 30. 2018
22.84
28 Trading Days
34.34%
Link
LONG
Sep 9. 2019
18.42
Sep 19. 2019
20.26
8 Trading Days
9.99%
Link
LONG
Oct 23. 2019
19.24
Nov 6. 2019
20.81
10 Trading Days
8.17%
Link
Company Information
Stock Symbol
HRTX
Exchange
NasdaqCM
Company URL
http://www.herontx.com
Company Phone
6503662626
CEO
Barry D. Quart
Headquarters
California
Business Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA 92121
Sector
Equity
Industry Category
Drugs
Industry Group
Drug Manufacturers - Major
CIK
0000818033
About

Heron Therapeutics, Inc. is a biotechnology company develops pharmaceutical products for patients suffering from cancer or pain. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its primary products are SUSTOL, HTX-019 and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bioerodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA

Description

Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.